Latest Conference Articles

Survival advantage was shown in a phase 3 study of neoadjuvant chemotherapy/carboplatin in patient with triple negative breast cancer.

Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.

Longer follow-up in the phase 3 STIC CTC trial substantiates that the CTC-based choice is safe in patients with metastatic breast cancer, according to investigators.

Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.

Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

The combination of palbociclib and fulvestrant beyond progression on prior CDK4/6 inhibitor did not show significant improvements in progression-free survival compared with fulvestrant alone in ER-positive/HER2-negative breast cancer.

Maryam Lustberg, MD, MPH, explains how the HER2 low session during the 2022 San Antonio Breast Cancer Symposium.

Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.

Findings from the phase 3 CAPItello-291 trial show that the combination of capivasertib plus fulvestrant achieved improvement in progression-free survival among patients with hormone-receptor–positive/HER2-negative advanced breast cancer.

Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.

The use of trastuzumab deruxtecan in the neoadjuvant setting showed promising responses in patients with early-stage breast cancer.

Patients with advanced HER2-positive breast cancer had better progression-free and overall survival outcomes when given trastuzumab deruxtecan versus capecitabin-based treatment.

Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in overall versus TDM-1 as well as a continued PFS benefit, according to Sara A. Hurvitz, MD.

According to Ruth O'Regan, MD, BCI is the first genomic assay to demonstrate benefit from ovarian suppression.

Among premenopausal patients, the addition of everolimus to endocrine therapy improved iDFS and OS, which is hypothesis generating, said Mariana Chavez-MacGregor, MD.

The data from 2 years post primary efficacy analysis of monarchE study showed that adjuvant abemaciclib plus endocrine therapy improves invasive disease-free survival.

Residual disease after neoadjuvant chemotherapy tumor microenvironment of metastasis doorway density is higher in Black women, potentially explaining poorer outcomes.

Pre- and postmenopausal patient with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, according to RxPONDER PRO substudy results presented during SABCS 2022.

Yielding a 46% reduction in the risk of disease progression of death compared with combination chemotherapy, ribociclib plus endocrine therapy may be a new standard of care for patients with pre/perimenopausal HR-positive, HER2-negative advanced breast cancer

During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.

According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.

Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.

In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.

Results presented at the 2022 International Kidney Cancer Symposium show tivozanib continues to demonstrate progression-free survival benefit over sorafenib in relapsed or refractory renal cell carcinoma.

After approximately 33 months of extended follow-up in the CLEAR study, investigators say lenvatinib plus pembrolizumab should be considered a standard of care option for frontline advanced renal cell carcinoma.

Subsequent therapy rates were lower in patients with advanced renal cell carcinoma treated with the combination of lenvatinib and pembrolizumab vs those who received sunitinib in the CLEAR trial.

The newly launched phase 2 LenCabo study of lenvatinib with everolimus vs cabozantinib for the second- or third-line treatment of metastatic renal cell carcinoma.

Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.

During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc

At the 14th International Congress on Myeloproliferative Neoplasms, research into the case of dizygotic twins with essential thrombocythemia won the Best overall Abstract Award for concluding how their rare stem cell disorder was passed between both twins.